Atara Biotherapeutics, Inc.
19.99%
1,370,081
1604464
046513107
May 13, 2025
May 16, 2025, 06:28 PM
Reporting Persons (3)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Adiumentum Capital Fund I LP | Investment Adviser | 19.99% | 1,370,081 | 0 | 1,370,081 |
| Adiumentum Capital Fund I GP LLC | Investment Adviser | 19.99% | 1,370,081 | 0 | 1,370,081 |
| Gregory A. Ciongoli | Investment Adviser | 19.99% | 1,370,081 | 0 | 1,370,081 |
Disclosure Items (6)
Common Stock, par value $0.0001 per share
Atara Biotherapeutics, Inc.
1280 Rancho Conejo Blvd, Thousand Oaks, CA, 91320
Item 3 of the Initial 13D is hereby amended and restated in its entirety as follows: The Responses to Item 4, 5 and 6 of this Schedule 13D are incorporated herein by reference. The investment costs (including commissions, if any) of the Common Stock and the Pre-Funded Warrants directly owned by Adiumentum is approximately $1,999,978.22. The source of funding for such transactions was derived from the capital of Adiumentum.
Items 5(a) and (b) of the Initial 13D are hereby amended and restated in their entirety to read as follows: The Reporting Persons each beneficially owns an aggregate of 1,370,081 shares of Common Stock (the "Subject Shares"). The Subject Shares represent approximately 19.99% of the outstanding shares of Common Stock, based on 6,639,146 shares of Common Stock outstanding as of May 16, 2025, as reported in the Issuer's prospectus supplement filed with the SEC on May 16, 2025, giving effect to the Registered Offering in which 75,572 shares of Common Stock and 227,000 Pre-Funded Warrants were issued to Adiumentum Capital Fund I LP. Adiumentum may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Shares. Adiumentum GP, as the general partner of Adiumentum may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares. Mr. Ciongoli, as the managing partner of Adiumentum, and as the managing member of Adiumentum GP, may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all the Subject Shares.
See response to Item 5(a) above.
Other than as disclosed in Item 4 of this Amendment No.2, no reportable transactions were effected by any Reporting Person during the past sixty days.
Item 6 of the Initial 13D is hereby amended and supplemented to add the information contained in Item 4 to this Amendment No. 2, which information is incorporated herein by reference.
Exhibit 99.3 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed by the Issuer with the SEC on May 16, 2024).